Global CAR-T Cell Therapy Market Overview:
Global CAR-T Cell Therapy Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global CAR-T Cell Therapy Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of CAR-T Cell Therapy involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the CAR-T Cell Therapy Market:
The CAR-T Cell Therapy Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for CAR-T Cell Therapy Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study CAR-T Cell Therapy Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, CAR-T Cell Therapy market has been segmented into:
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
and Others
By Application, CAR-T Cell Therapy market has been segmented into:
Leukemia
Lymphoma
Multiple Myeloma
and Autoimmune Disorders
and Other Applications
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The CAR-T Cell Therapy market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the CAR-T Cell Therapy market.
Top Key Players Covered in CAR-T Cell Therapy market are:
Novartis AG
Bristol-Myers Squibb Company
Johnson & Johnson
Sorrento Therapeutics
Inc.
Gilead Sciences
Inc. (Kite Pharma)
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Industry Dynamics and Opportunity Analysis
3.1.1 Growth Drivers
3.1.2 Limiting Factors
3.1.3 Growth Opportunities
3.1.4 Challenges and Risks
3.2 Market Trend Analysis
3.3 Strategic Pestle Overview
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Mapping
3.6 Regulatory Framework
3.7 Princing Trend Analysis
3.8 Patent Analysis
3.9 Technology Evolution
3.10 Investment Pockets
3.11 Import-Export Analysis
Chapter 4: CAR-T Cell Therapy Market Type
4.1 CAR-T Cell Therapy Market Snapshot and Growth Engine
4.2 CAR-T Cell Therapy Market Overview
4.3 Abecma
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Abecma: Geographic Segmentation Analysis
4.4 Breyanzi
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Breyanzi: Geographic Segmentation Analysis
4.5 Kymriah
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Kymriah: Geographic Segmentation Analysis
4.6 Tecartus
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Tecartus: Geographic Segmentation Analysis
4.7 Yescarta
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Yescarta: Geographic Segmentation Analysis
4.8 and Others
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 and Others: Geographic Segmentation Analysis
Chapter 5: CAR-T Cell Therapy Market Application
5.1 CAR-T Cell Therapy Market Snapshot and Growth Engine
5.2 CAR-T Cell Therapy Market Overview
5.3 Leukemia
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Leukemia: Geographic Segmentation Analysis
5.4 Lymphoma
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Lymphoma: Geographic Segmentation Analysis
5.5 Multiple Myeloma
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Multiple Myeloma: Geographic Segmentation Analysis
5.6 and Autoimmune Disorders
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 and Autoimmune Disorders: Geographic Segmentation Analysis
5.7 and Other Applications
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 and Other Applications: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 CAR-T Cell Therapy Market Share by Manufacturer (2023)
6.1.3 Concentration Ratio(CR5)
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 NOVARTIS AG
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Operating Business Segments
6.2.5 Product Portfolio
6.2.6 Business Performance
6.2.7 Key Strategic Moves and Recent Developments
6.3 BRISTOL-MYERS SQUIBB COMPANY
6.4 JOHNSON & JOHNSON
6.5 SORRENTO THERAPEUTICS
6.6 INC.
6.7 GILEAD SCIENCES
6.8 INC. (KITE PHARMA)
Chapter 7: Global CAR-T Cell Therapy Market By Region
7.1 Overview
7.2. North America CAR-T Cell Therapy Market
7.2.1 Historic and Forecasted Market Size by Segments
7.2.2 Historic and Forecasted Market Size By Type
7.2.2.1 Abecma
7.2.2.2 Breyanzi
7.2.2.3 Kymriah
7.2.2.4 Tecartus
7.2.2.5 Yescarta
7.2.2.6 and Others
7.2.3 Historic and Forecasted Market Size By Application
7.2.3.1 Leukemia
7.2.3.2 Lymphoma
7.2.3.3 Multiple Myeloma
7.2.3.4 and Autoimmune Disorders
7.2.3.5 and Other Applications
7.2.4 Historic and Forecast Market Size by Country
7.2.4.1 US
7.2.4.2 Canada
7.2.4.3 Mexico
7.3. Eastern Europe CAR-T Cell Therapy Market
7.3.1 Historic and Forecasted Market Size by Segments
7.3.2 Historic and Forecasted Market Size By Type
7.3.2.1 Abecma
7.3.2.2 Breyanzi
7.3.2.3 Kymriah
7.3.2.4 Tecartus
7.3.2.5 Yescarta
7.3.2.6 and Others
7.3.3 Historic and Forecasted Market Size By Application
7.3.3.1 Leukemia
7.3.3.2 Lymphoma
7.3.3.3 Multiple Myeloma
7.3.3.4 and Autoimmune Disorders
7.3.3.5 and Other Applications
7.3.4 Historic and Forecast Market Size by Country
7.3.4.1 Russia
7.3.4.2 Bulgaria
7.3.4.3 The Czech Republic
7.3.4.4 Hungary
7.3.4.5 Poland
7.3.4.6 Romania
7.3.4.7 Rest of Eastern Europe
7.4. Western Europe CAR-T Cell Therapy Market
7.4.1 Historic and Forecasted Market Size by Segments
7.4.2 Historic and Forecasted Market Size By Type
7.4.2.1 Abecma
7.4.2.2 Breyanzi
7.4.2.3 Kymriah
7.4.2.4 Tecartus
7.4.2.5 Yescarta
7.4.2.6 and Others
7.4.3 Historic and Forecasted Market Size By Application
7.4.3.1 Leukemia
7.4.3.2 Lymphoma
7.4.3.3 Multiple Myeloma
7.4.3.4 and Autoimmune Disorders
7.4.3.5 and Other Applications
7.4.4 Historic and Forecast Market Size by Country
7.4.4.1 Germany
7.4.4.2 UK
7.4.4.3 France
7.4.4.4 The Netherlands
7.4.4.5 Italy
7.4.4.6 Spain
7.4.4.7 Rest of Western Europe
7.5. Asia Pacific CAR-T Cell Therapy Market
7.5.1 Historic and Forecasted Market Size by Segments
7.5.2 Historic and Forecasted Market Size By Type
7.5.2.1 Abecma
7.5.2.2 Breyanzi
7.5.2.3 Kymriah
7.5.2.4 Tecartus
7.5.2.5 Yescarta
7.5.2.6 and Others
7.5.3 Historic and Forecasted Market Size By Application
7.5.3.1 Leukemia
7.5.3.2 Lymphoma
7.5.3.3 Multiple Myeloma
7.5.3.4 and Autoimmune Disorders
7.5.3.5 and Other Applications
7.5.4 Historic and Forecast Market Size by Country
7.5.4.1 China
7.5.4.2 India
7.5.4.3 Japan
7.5.4.4 South Korea
7.5.4.5 Malaysia
7.5.4.6 Thailand
7.5.4.7 Vietnam
7.5.4.8 The Philippines
7.5.4.9 Australia
7.5.4.10 New Zealand
7.5.4.11 Rest of APAC
7.6. Middle East & Africa CAR-T Cell Therapy Market
7.6.1 Historic and Forecasted Market Size by Segments
7.6.2 Historic and Forecasted Market Size By Type
7.6.2.1 Abecma
7.6.2.2 Breyanzi
7.6.2.3 Kymriah
7.6.2.4 Tecartus
7.6.2.5 Yescarta
7.6.2.6 and Others
7.6.3 Historic and Forecasted Market Size By Application
7.6.3.1 Leukemia
7.6.3.2 Lymphoma
7.6.3.3 Multiple Myeloma
7.6.3.4 and Autoimmune Disorders
7.6.3.5 and Other Applications
7.6.4 Historic and Forecast Market Size by Country
7.6.4.1 Turkiye
7.6.4.2 Bahrain
7.6.4.3 Kuwait
7.6.4.4 Saudi Arabia
7.6.4.5 Qatar
7.6.4.6 UAE
7.6.4.7 Israel
7.6.4.8 South Africa
7.7. South America CAR-T Cell Therapy Market
7.7.1 Historic and Forecasted Market Size by Segments
7.7.2 Historic and Forecasted Market Size By Type
7.7.2.1 Abecma
7.7.2.2 Breyanzi
7.7.2.3 Kymriah
7.7.2.4 Tecartus
7.7.2.5 Yescarta
7.7.2.6 and Others
7.7.3 Historic and Forecasted Market Size By Application
7.7.3.1 Leukemia
7.7.3.2 Lymphoma
7.7.3.3 Multiple Myeloma
7.7.3.4 and Autoimmune Disorders
7.7.3.5 and Other Applications
7.7.4 Historic and Forecast Market Size by Country
7.7.4.1 Brazil
7.7.4.2 Argentina
7.7.4.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
CAR-T Cell Therapy Scope:
|
Report Data
|
CAR-T Cell Therapy Market
|
|
CAR-T Cell Therapy Market Size in 2025
|
USD XX million
|
|
CAR-T Cell Therapy CAGR 2025 - 2032
|
XX%
|
|
CAR-T Cell Therapy Base Year
|
2024
|
|
CAR-T Cell Therapy Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, Sorrento Therapeutics, Inc., Gilead Sciences, Inc. (Kite Pharma).
|
|
Key Segments
|
By Type
Abecma
Breyanzi
Kymriah
Tecartus
Yescarta
and Others
By Applications
Leukemia
Lymphoma
Multiple Myeloma
and Autoimmune Disorders
and Other Applications
|
